Ketoacidosis as unexpected adverse reaction SGLT2 inhibitor
Abstract
Inhibitors of the sodium-glucose cotransporter-2 SGLT2 is a new class of hypoglycemic drugs. This article presents the information on FDA reports (2013-2015) and AIS (May 2015 - February 2016) on the risk of new adverse reaction - ketoacidosis. Conjectural pathophysiological mechanisms of ADR associated with this class of drugs, which could lead to its development are presented.
About the Authors
T. M. Bukatina
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
A. S. Kazakov
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
N. Yu. Velts
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
M. A. Darmostukova
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
K. E. Zatolochina
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
R. N. Alyautdin
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
V. P. Dobrynin
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
B. K. Romanov
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
References
1. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. ¹ Engl J Med. 2008; 359: 1577–89.
2. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287: 360–72.
3. Tahir H, Wani A, Daruwalla V, Daboul N, Sagi J. Euglycemic diabetic ketoacidosis and severe acute kidney injury secondary to off label use of sodium glucose cotransporter-2 inhibitor in a type-1 diabetic patient. J Ayub Med Coll Abbottabad 2015; 27 (4): 923–4.
4. Storgaard H, Bagger JI, Knop FK, Vilsboll T, Rungby J. Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment. Basic Clin Pharmacol Toxicol. 2016; 118 (2): 168–70.
5. Bukatina TM, Pasternak EYu, Velts NYu, et al. Inhibitors of sodium-glucose cotransporter 2: risk of ketoacidosis. Safety & Risk of Pharmacotherapy 2016; 2: 33–9 (in Russian).
6. Jung ChH, Jang JE, and Park J-Y. A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor. Diabetes Metab J. 2014; 38 (4): 261–73.
7. Ushkalova ÅÀ. A new class of antidiabetic drugs – inhibitors of sodium-glucose cotranporter. Pharmatheka 2013; 16: 33–6 (in Russian).
8. Canagliflozin, Dapagliflozin, Empagliflozin. Label Information. [Internet]. 2016 [cited 15.08.2016]. Avaible at: http://www.grls.rosminzdrav.ru/grls.aspx/ (in Russian).
9. Lam KS, Chow CC, Tan KC, et al. Practical considerations for the use of sodium- glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes. Curr Med Res Opin. 2016; 4: 1–12.
10. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections [Internet]. 2015 [cited 16.08.2016].Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm.
11. Surya PR, Wilding. JP. SGLT2 inhibition and ketoacidosis – should we be concerned? Br. J. Diabetes Vasc Dis. 2015; 15: 155–8.
Review
For citations:
Bukatina T.M., Kazakov A.S., Velts N.Yu., Darmostukova M.A., Zatolochina K.E., Alyautdin R.N., Dobrynin V.P., Romanov B.K. Ketoacidosis as unexpected adverse reaction SGLT2 inhibitor. Safety and Risk of Pharmacotherapy. 2016;(4):23-26. (In Russ.)
Views:
1286
Email this article 